Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia

Leukemia. 2018 Sep;32(9):2025-2028. doi: 10.1038/s41375-018-0225-7. Epub 2018 Aug 6.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical / methods
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Janus Kinase 1 / antagonists & inhibitors*
  • Janus Kinase 2 / antagonists & inhibitors*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / metabolism*
  • Leukemia, Myeloid, Acute / pathology
  • Molecular Targeted Therapy
  • Mutation
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Proto-Oncogene Proteins c-bcl-2
  • JAK1 protein, human
  • JAK2 protein, human
  • Janus Kinase 1
  • Janus Kinase 2